Zhejiang Starry Pharmaceutical Co.,Ltd. Stock: price and insider trades · China
司太立
1 insider bought €7.2M of shares over the last 90 days, the latest by 胡思慧, filed 12 Aug 2026.
Zhejiang Starry Pharmaceutical Co.,Ltd.: what insiders have been doing
Zhejiang Starry Pharmaceutical Co.,Ltd. belongs to the Health Care sector. Filings by its managers are published through SSE / SZSE (CSRC). The last twelve months, up to 4 November 2026, brought 5 filings signed by 3 insiders.
Both sides are active: 1 purchase worth €7.2M and 4 sales worth €1.8M, from 1 insider and 2 insiders respectively. Netting one side against the other leaves €5.4M of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 board member among the declarants. Biggest ticket of the year: €7.2M, bought by 胡思慧 and made public on 12 August 2026.
The most recent open-market purchase was published on 12 August 2026, 88 days ago. Publication is fast: at least half of the trades appear on SSE / SZSE (CSRC) on the same day. Until a filing is published, the market cannot know about the trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 516 companies) published 2 filings over the same period, against 5 filings here. Since 2022, the database holds 3 purchases and 6 sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -10.3%Entry CN¥9.01 · Close 03 Nov 2026 CN¥8.08
- -48.5%Entry CN¥31.79 · Close at T+365 CN¥16.38
- -49.2%Entry CN¥32.88 · Close at T+365 CN¥16.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 6,883,035 shares@ CN¥63.0374100.0% of flowA股XSHGSSE:273000001184851600Canonical exit: 10 Nov 2026 (T+90)
- 586,098 shares@ CN¥68.652612.5% of flowA股XSHGSSE:273000001058868860
- 500,000 shares@ CN¥65.60310.3% of flowA股XSHGSSE:273000000870540260
- 400,000 shares@ CN¥83.847510.5% of flowA股XSHGSSE:273000000778600220
- 7,100 shares100.0% of flowA股XSHGSSE:273000000597979650
- 715,860 shares28.1% of flowA股XSHGSSE:173000006758729570
- 994,040 shares38.6% of flowA股XSHGSSE:173000006758887040
- 4,880 shares100.0% of flowA股XSHGSSE:173000005724614100Canonical exit: 5 Sept 2022 (T+90)
- 4,000 shares100.0% of flowA股XSHGSSE:173000005724618980Canonical exit: 17 Aug 2022 (T+90)
9 of 9 declarations
About Zhejiang Starry Pharmaceutical Co.,Ltd.
司太立 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHG market. It specializes in the development and production of medicines and pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
